Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status

European Urology

Volumn 67, Issue 3, 2015, Pages 441-447

  Azad, Arun A ^a   Eigl, Bernhard J ^a   Leibowitz Amit, Raya ^b   Lester, Renee ^c   Kollmannsberger, Christian ^a   Murray, Nevin ^a   Clayton, Ravinder ^c   Heng, Daniel Y C ^c   Joshua, Anthony M ^b   Chi, Kim N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Abiraterone acetate; Castration resistant prostate cancer; ECOG; Performance status; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P450 INHIBITOR; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; STEROID SYNTHESIS INHIBITOR;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; FISHER EXACT TEST; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; HEALTH STATUS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; STATISTICAL MODEL; TIME; VERY ELDERLY;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CANADA; CYTOCHROME P-450 ENZYME INHIBITORS; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; RISK FACTORS; STEROID SYNTHESIS INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922248732     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.01.030     Document Type: Article

References (14)

1. N. Agarwal, G. Sonpavde, and C.N. Sternberg Novel molecular targets for the therapy of castration-resistant prostate cancer Eur Urol 61 2012 950 960
2. A. Heidenreich, P.J. Bastian, and J. Bellmunt EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
3. Y. Chen, C.L. Sawyers, and H.I. Scher Targeting the androgen receptor pathway in prostate cancer Curr Opin Pharmacol 8 2008 440 448
4. C.J. Ryan, M.R. Smith, J.S. de Bono COU-AA-302 Investigators Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
5. J.S. de Bono, C.J. Logothetis, A. Molina COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
6. R. Clayton, D.Y.C. Heng, and J.S.Y. Wu A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract] J Clin Oncol 31 Suppl 6 2013 113
7. H.I. Scher, S. Halabi, I. Tannock Prostate Cancer Clinical Trials Working Group Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
8. K.N. Chi, T.S. Kheoh, and C.J. Ryan A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel [abstract] J Clin Oncol 31 Suppl 2013 5013
9. N. Wilcken, J. Hornbuckle, and D. Ghersi Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Syst Rev 2003 CD002747
10. I.F. Tannock, R. de Wit, W.R. Berry TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
11. H.I. Scher, K. Fizazi, F. Saad AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
12. J.S. de Bono, S. Oudard, M. Ozguroglu TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
13. C. Parker, S. Nilsson, D. Heinrich ALSYMPCA Investigators Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
14. P.W. Kantoff, C.S. Higano, N.D. Shore IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422